Emergent BioSolutions (EBS) Reports Q1 Loss of $3.17
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $5.94 +4.58%
EPS Growth %: -138.7%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -138.7%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
(Updated - May 9, 2023 5:00 PM EDT)
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of ($3.17), versus $0.00 reported last year. Revenue for the quarter came in at $165.1 million versus the consensus estimate of $175.12 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle reports earnings today: AI spending bet faces its toughest test yet
- Academy Sports & Outdoors Inc. (ASO) PT Raised to $47 at BMO Capital
- Morgan Stanley cautious on Coinbase, but target implies over 40% upside
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
